Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free IPHA Stock Alerts

Innate Pharma (IPHA) Financials

Innate Pharma logo
$1.77 -0.02 (-1.34%)
As of 07/10/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Innate Pharma

Annual Income Statements for Innate Pharma

This table shows Innate Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -58 3.49 -23 -78 -60 -62 -8.37 -51 -58
Consolidated Net Income / (Loss)		 -58 3.49 -23 -78 -60 -62 -8.37 -51 -58
Net Income / (Loss) Continuing Operations		 -58 3.49 8.83 -1.01 -51 -62 -8.37 -51 -58
Total Pre-Tax Income 		-58 3.11 8.83 -1.01 -51 -62 -8.37 -51 -58
Total Operating Income		 -61 7.16 -3.82 -6.94 -59 -67 -16 -57 -67
Total Gross Profit		 53 108 96 85 28 62 68 21 11
Total Revenue		 53 108 96 85 28 62 68 21 11
Operating Revenue		 53 91 96 69 14 53 57 13 3.29
Other Revenue		 - 16 - 17 14 8.60 11 7.75 7.28
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 114 100 100 92 87 129 84 78 78
Selling, General & Admin Expense		 20 21 24 23 29 24 20 20 23
Research & Development Expense		 80 80 71 61 53 55 62 54 51
Other Operating Expenses / (Income)		 13 - 5.58 8.26 4.52 5.69 2.03 4.11 3.66
Impairment Charge		 - 0.00 - 0.00 0.00 44 0.00 0.00 0.00
Total Other Income / (Expense), net		 3.00 -4.05 13 5.93 7.18 5.11 7.67 6.29 9.33
Interest & Investment Income		 3.00 6.87 - 5.93 7.18 5.11 7.67 6.29 9.33
Income Tax Expense		 0.44 -0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.89) $0.05 - ($0.81) ($0.66) ($0.78) ($0.10) ($0.63) ($0.65)
Weighted Average Basic Shares Outstanding		 - - 78.58M 78.99M 79.54M 79.54M 80.45M 83.83M 93.72M
Diluted Earnings per Share		 ($0.89) $0.05 - ($0.81) ($0.66) ($0.78) ($0.10) ($0.63) ($0.65)
Weighted Average Diluted Shares Outstanding		 - - 78.58M 78.99M 79.54M 79.54M 80.45M 83.83M 93.72M
Weighted Average Basic & Diluted Shares Outstanding		 - - 78.58M 78.99M 79.54M 79.54M 80.45M 83.83M 93.72M

Quarterly Income Statements for Innate Pharma

No quarterly income statements for Innate Pharma are available.

Annual Cash Flow Statements for Innate Pharma

This table details how cash moves in and out of Innate Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -92 61 57 -81 -37 -21 -15 -13 -45
Net Cash From Operating Activities		 -58 -37 39 -63 -66 -20 -36 -9.61 -62
Net Cash From Continuing Operating Activities		 -58 6.09 39 -63 -66 -20 -37 -9.61 -62
Net Income / (Loss) Continuing Operations		 -58 3.49 -23 -78 -60 -62 -8.37 -51 -58
Consolidated Net Income / (Loss)		 -58 3.49 -23 -78 -60 -62 -8.37 -51 -58
Depreciation Expense		 5.28 - 19 69 5.20 49 5.63 2.06 1.62
Non-Cash Adjustments To Reconcile Net Income		 17 2.60 -1.22 5.65 -0.41 6.47 1.71 47 7.04
Changes in Operating Assets and Liabilities, net		 -22 - 45 -60 -11 -13 -36 -7.29 -12
Net Cash From Investing Activities		 -35 28 -70 -16 -1.04 2.01 23 0.00 8.55
Net Cash From Continuing Investing Activities		 -36 28 -70 -16 -1.04 -1.20 23 0.00 0.30
Purchase of Property, Plant & Equipment		 -3.56 -1.00 -1.43 -1.11 -1.05 -0.57 -0.39 - -0.16
Acquisitions		 - 0.03 -0.01 -0.07 -0.00 -0.00 -0.00 - 0.00
Purchase of Investments		 -56 -0.64 -72 -16 -0.45 -0.63 -2.21 - 0.00
Sale of Property, Plant & Equipment		 0.06 0.03 0.00 0.01 0.05 0.00 0.24 - 0.01
Sale and/or Maturity of Investments		 21 28 2.24 0.00 0.00 0.00 25 - 0.00
Other Investing Activities, net		 1.73 1.65 1.45 1.18 0.42 - 0.00 - 0.46
Net Cash From Financing Activities		 1.10 70 87 -1.44 30 -1.96 -2.17 -3.19 7.12
Net Cash From Continuing Financing Activities		 1.10 70 87 -1.44 30 -1.96 -2.17 -3.19 7.12
Repayment of Debt		 -1.44 -1.54 -2.22 -2.74 -2.34 -2.17 -2.61 - -10
Issuance of Common Equity		 - 0.13 0.05 0.06 0.56 0.21 0.44 3.03 18
Effect of Exchange Rate Changes		 0.08 -0.03 0.01 0.27 -0.55 -0.46 0.30 - 1.28

Quarterly Cash Flow Statements for Innate Pharma

No quarterly cash flow statements for Innate Pharma are available.

Annual Balance Sheets for Innate Pharma

This table presents Innate Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 306 516 450 376 303 213 194 115 74
Total Current Assets		 165 366 267 212 156 150 164 89 55
Cash & Equivalents		 119 174 228 167 117 90 78 69 33
Short-Term Investments		 20 17 18 18 18 18 24 15 7.30
Accounts Receivable		 26 174 21 27 21 41 61 5.15 15
Plant, Property, & Equipment, net		 13 12 13 14 0.00 71 15 57 63
Plant, Property & Equipment, gross		 13 12 13 14 - 71 15 57 63
Total Noncurrent Assets		 128 138 171 149 134 -47 -62 -45 -44
Long-Term Investments		 - -0.75 -0.13 -0.83 -0.73 -1.65 -0.19 -0.21 -4.08
Noncurrent Note & Lease Receivables		 - 0.00 19 36 34 15 12 9.66 0.29
Intangible Assets		 55 97 109 57 50 1.66 0.46 0.00 0.00
Other Noncurrent Operating Assets		 73 40 42 48 45 -62 -74 -55 -40
Total Liabilities & Shareholders' Equity		 306 516 450 376 303 213 194 115 74
Total Liabilities		 203 324 206 184 135 54 51 40 41
Total Current Liabilities		 89 224 137 41 67 43 44 34 39
Accounts Payable		 30 105 56 36 32 22 19 17 18
Accrued Expenses		 - 1.54 26 4.85 35 13 18 17 18
Current Deferred Revenue		 58 94 - - - 7.02 6.49 0.64 3.32
Total Noncurrent Liabilities		 114 100 70 143 68 11 7.81 5.75 2.26
Noncurrent Deferred Revenue		 105 82 100 54 43 8.47 5.11 2.92 0.00
Noncurrent Employee Benefit Liabilities		 3.15 - 4.22 5.10 3.37 2.73 2.70 2.83 2.26
Total Equity & Noncontrolling Interests		 103 191 244 191 122 178 123 69 6.77
Total Preferred & Common Equity		 161 191 244 191 181 120 66 60 32
Total Common Equity		 161 191 244 191 181 120 66 60 32
Common Stock		 286 3.66 419 459 429 4.29 4.47 4.34 5.50
Retained Earnings		 -124 -158 -151 -191 -248 -291 -364 -349 -453
Other Equity Adjustments		 0.22 346 -24 -78 0.52 407 426 405 480
Noncontrolling Interest		 - - - - - 58 57 9.14 -25

Quarterly Balance Sheets for Innate Pharma

No quarterly balance sheets for Innate Pharma are available.

Annual Metrics And Ratios for Innate Pharma

This table displays calculated financial ratios and metrics derived from Innate Pharma's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 78,580,464.00 78,986,490.00 79,542,627.00 79,542,627.00 80,453,282.00 83,830,336.00 93,719,323.00
DEI Adjusted Shares Outstanding		 0.00 0.00 78,580,464.00 78,986,490.00 79,542,627.00 79,542,627.00 80,453,282.00 83,830,336.00 93,719,323.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.30 -0.99 -0.75 -0.78 -0.10 -0.61 -0.62
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 103.29% -10.82% -11.12% -67.20% 120.68% 10.51% -69.46% -49.26%
EBITDA Growth		 0.00% 110.63% 364.88% 128.05% -185.60% 65.29% 43.87% -432.39% -18.01%
EBIT Growth		 0.00% 109.71% 49.92% -178.64% -744.69% -14.45% 76.10% -258.38% -16.60%
NOPAT Growth		 0.00% 118.92% -147.50% -27.35% -744.69% -14.45% 76.10% -258.38% -16.60%
Net Income Growth		 0.00% 106.00% -767.61% -235.51% 23.53% -4.00% 86.53% -511.51% -12.71%
EPS Growth		 0.00% 105.62% 0.00% 0.00% 18.52% -18.33% 87.25% -533.94% -2.23%
Operating Cash Flow Growth		 0.00% 35.51% 205.28% -261.35% -4.62% 69.03% -75.76% 73.33% -544.55%
Free Cash Flow Firm Growth		 0.00% 0.00% 131.48% -458.67% 106.27% -650.36% 259.69% -239.93% -23.40%
Invested Capital Growth		 0.00% 238.04% -57.48% 376.63% -55.63% -63.63% -375.58% 36.53% 82.89%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -104.75% 5.48% 28.55% 73.26% -191.18% -30.07% -15.27% -266.17% -619.05%
Operating Margin		 -114.73% 6.66% -3.98% -8.15% -209.78% -108.79% -23.53% -276.08% -634.41%
EBIT Margin		 -114.73% 5.48% 9.21% -8.15% -209.78% -108.79% -23.53% -276.08% -634.41%
Profit (Net Income) Margin		 -109.88% 3.25% -24.29% -91.70% -213.78% -100.74% -12.28% -245.87% -546.11%
Tax Burden Percent		 100.77% 112.18% -263.84% 7,718.21% 116.12% 100.23% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.05% 52.82% 100.00% 14.58% 87.76% 92.39% 52.19% 89.06% 86.08%
Effective Tax Rate		 0.00% -12.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 144.80% -13.30% -9.84% -69.68% -190.29% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 148.01% -2.99% 33.82% -50.42% -178.17% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -142.43% 2.60% -26.13% 31.39% 148.80% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -56.29% 2.37% -10.70% -35.98% -38.30% -41.49% -5.56% -53.15% -151.35%
Cash Return on Invested Capital (CROIC)		 0.00% -152.49% 67.37% -140.48% 7.38% -96.97% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -19.81% 1.43% 1.83% -1.68% -17.29% -26.02% -7.88% -37.25% -71.11%
Return on Assets (ROA)		 -18.97% 0.85% -4.82% -18.93% -17.62% -24.09% -4.12% -33.17% -61.21%
Return on Common Equity (ROCE)		 -87.98% 2.84% -10.70% -35.98% -45.63% -41.75% -3.43% -34.79% -183.75%
Return on Equity Simple (ROE_SIMPLE)		 -36.02% 1.82% -9.55% -41.02% -32.95% -51.76% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -42 8.04 -3.82 -4.86 -41 -47 -11 -40 -47
NOPAT Margin		 -80.31% 7.47% -3.98% -5.70% -146.85% -76.16% -16.47% -193.26% -444.09%
Net Nonoperating Expense Percent (NNEP)		 -11.81% -3.21% -10.31% -43.66% -19.26% -12.13% 1.76% -8.70% -20.89%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -26.39% -9.12% -57.92% -693.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 38.64% 19.31% 24.55% 27.21% 103.32% 38.90% 29.67% 97.99% 215.37%
R&D to Revenue		 152.16% 74.03% 73.61% 71.24% 190.28% 89.58% 90.88% 258.34% 484.40%
Operating Expenses to Revenue		 214.73% 93.34% 103.98% 108.15% 309.78% 208.79% 123.53% 376.08% 734.41%
Earnings before Interest and Taxes (EBIT)		 -61 5.89 8.83 -6.94 -59 -67 -16 -57 -67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -55 5.89 27 62 -53 -19 -10 -55 -65
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.50 0.42 0.28 1.69 1.99 2.47 3.39 2.45 4.55
Price to Tangible Book Value (P/TBV)		 0.76 0.85 0.51 2.40 2.74 2.51 3.41 2.45 4.55
Price to Revenue (P/Rev)		 1.51 0.74 0.72 3.77 12.88 4.81 3.27 7.11 13.88
Price to Earnings (P/E)		 0.00 22.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 4.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 1.93 6.64 18.81 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 1.85 8.60 4.01 2.61 3.54 8.05
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 2.53 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 55.29 0.00 4.66 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.07 0.02 0.08 0.11 0.13 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.05 0.02 0.08 0.11 0.13 0.00 0.00 0.00 0.00
Financial Leverage		 -1.28 -0.96 -0.87 -0.77 -0.62 -0.84 -1.08 -1.31 -1.35
Leverage Ratio		 2.97 2.79 2.22 1.90 2.17 1.72 1.35 1.60 2.47
Compound Leverage Factor		 2.82 1.47 2.22 0.28 1.91 1.59 0.71 1.43 2.13
Debt to Total Capital		 6.39% 1.86% 7.09% 9.80% 11.16% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.92% 1.86% 7.09% 9.80% 11.16% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 32.54% 46.60% 13.16% -376.24%
Common Equity to Total Capital		 146.31% 98.14% 92.91% 90.20% 132.50% 67.46% 53.40% 86.84% 476.24%
Debt to EBITDA		 -0.13 0.62 0.68 0.33 -0.29 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.39 -31.81 -8.29 -2.62 2.24 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.10 0.62 0.68 0.33 -0.29 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.17 0.45 -4.88 -4.26 -0.37 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 3.12 -23.32 59.44 33.68 2.91 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.13 0.45 -4.88 -4.26 -0.37 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.51 0.29 0.35 1.05 0.26 1.25 0.79 -2.91 -9.09
Noncontrolling Interest Sharing Ratio		 -56.29% -19.72% 0.00% 0.00% -19.15% -0.61% 38.29% 34.54% -21.41%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 1.86 1.63 1.95 5.18 2.33 3.51 3.75 2.62 1.41
Quick Ratio		 1.86 1.63 1.95 5.18 2.33 3.51 3.75 2.62 1.41
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -61 19 -69 4.35 -24 38 -54 -66
Operating Cash Flow to CapEx		 -1,649.28% -3,822.44% 2,747.76% -5,764.70% -6,627.78% -3,580.37% -24,117.78% 0.00% -39,077.78%
Free Cash Flow to Firm to Interest Expense		 0.00 -6.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -3.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -3.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.17 0.26 0.20 0.21 0.08 0.24 0.34 0.13 0.11
Accounts Receivable Turnover		 2.06 1.08 0.98 3.58 1.18 1.99 1.33 0.63 1.07
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.10 8.75 7.74 6.23 0.00 0.00 1.57 0.58 0.18
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 177.49 339.13 371.34 102.09 310.03 183.00 274.28 583.62 340.18
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 177.49 339.13 371.34 102.09 310.03 183.00 274.28 583.62 340.18
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -29 40 17 82 36 13 -36 -23 -3.94
Invested Capital Turnover		 -1.81 19.38 3.34 1.73 0.47 2.50 -5.90 -0.70 -0.78
Increase / (Decrease) in Invested Capital		 0.00 69 -23 64 -45 -23 -49 13 19
Enterprise Value (EV)		 -52 -107 -158 158 241 248 178 74 85
Market Capitalization		 80 80 69 321 360 297 223 148 147
Book Value per Share		 $15.13 $17.94 $3.11 $2.42 $2.30 $1.51 $0.82 $0.75 $0.38
Tangible Book Value per Share		 $9.93 $8.87 $1.72 $1.71 $1.66 $1.49 $0.81 $0.75 $0.38
Total Capital		 110 195 263 211 137 178 123 69 6.77
Total Debt		 7.04 3.63 19 21 15 0.00 0.00 0.00 0.00
Total Long-Term Debt		 5.43 3.63 19 21 15 0.00 0.00 0.00 0.00
Net Debt		 -132 -187 -227 -164 -120 -107 -102 -83 -36
Capital Expenditures (CapEx)		 3.50 0.97 1.43 1.10 1.00 0.57 0.15 0.00 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -61 -50 -116 -14 -46 -1.55 18 -29 -24
Debt-free Net Working Capital (DFNWC)		 78 141 130 171 89 107 120 55 16
Net Working Capital (NWC)		 76 141 130 171 89 107 120 55 16
Net Nonoperating Expense (NNE)		 16 4.55 19 73 19 15 -2.86 11 11
Net Nonoperating Obligations (NNO)		 -132 -151 -227 -109 -85 -165 -159 -93 -11
Total Depreciation and Amortization (D&A)		 5.28 0.00 19 69 5.20 49 5.63 2.06 1.62
Debt-free, Cash-free Net Working Capital to Revenue		 -116.17% -46.80% -120.64% -16.77% -165.57% -2.51% 26.10% -138.18% -230.65%
Debt-free Net Working Capital to Revenue		 147.51% 131.51% 135.50% 200.56% 319.54% 173.45% 176.10% 263.24% 150.36%
Net Working Capital to Revenue		 144.46% 131.51% 135.50% 200.56% 319.54% 173.45% 176.10% 263.24% 150.36%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.31) $0.00 $0.00 ($0.73) ($0.09) ($0.63) ($0.65)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 78.58M 78.99M 79.54M 79.54M 80.45M 83.83M 93.72M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.31) $0.00 $0.00 ($0.73) ($0.09) ($0.63) ($0.65)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 78.58M 78.99M 79.54M 79.54M 80.45M 83.83M 93.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 78.58M 78.99M 79.54M 79.54M 80.45M 83.83M 93.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -42 5.01 -2.67 -4.86 -41 -16 -11 -40 -47
Normalized NOPAT Margin		 -80.31% 4.66% -2.79% -5.70% -146.85% -26.39% -16.47% -193.26% -444.09%
Pre Tax Income Margin		 -109.05% 2.89% 9.21% -1.19% -184.10% -100.52% -12.28% -245.87% -546.11%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Innate Pharma

No quarterly metrics and ratios for Innate Pharma are available.


Financials Breakdown Chart

Innate Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Innate Pharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Innate Pharma's net income appears to be on an upward trend, with a most recent value of -$57.71 million in 2025, falling from -$58.12 million in 2017. The previous period was -$51.21 million in 2024. Check out Innate Pharma's forecast to explore projected trends and price targets.

Innate Pharma's total operating income in 2025 was -$67.05 million, based on the following breakdown:
  • Total Gross Profit: $10.57 million
  • Total Operating Expenses: $77.61 million

Over the last 8 years, Innate Pharma's total revenue changed from $52.89 million in 2017 to $10.57 million in 2025, a change of -80.0%.

Innate Pharma's total liabilities were at $41.19 million at the end of 2025, a 3.8% increase from 2024, and a 79.7% decrease since 2017.

In the past 8 years, Innate Pharma's cash and equivalents has ranged from $32.97 million in 2025 to $227.69 million in 2019, and is currently $32.97 million as of their latest financial filing in 2025.

Over the last 8 years, Innate Pharma's book value per share changed from 15.13 in 2017 to 0.38 in 2025, a change of -97.5%.


Related Companies

Financial statements for NASDAQ:IPHA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel